On July 10, AstraZeneca fell 3.11% in regular trading, trading at $172.75/share with turnover of $103 million. The stock extended the prior session's sharp decline, continuing to face downward pressure.

The selloff is a continuation of the impact from AstraZeneca and Ionis Pharmaceuticals' jointly developed cardiac drug Wainua (eplontersen) failing to meet the primary efficacy endpoint in a Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial's primary endpoint was a composite outcome of cardiovascular mortality and recurrent cardiovascular clinical events up to week 140. Adding eplontersen to standard of care, including stabilizer therapy, did not provide a statistically significant benefit versus placebo. AstraZeneca and Ionis plan to present full data at the European Society of Cardiology Congress in August. The prior session saw AstraZeneca drop approximately 7.8%, marking its worst performance since March 2020.

Within the Pharmacy sector, the overall tone remained subdued. Among peers, Eli Lilly down 1.8%, Johnson & Johnson down 0.11%, Merck down 0.64%, Pfizer up 0.47%, confirming the decline remains an idiosyncratic event-driven selloff rather than a sector-wide move.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)